Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 64Cisplatin 44Cetuximab 26Carboplatin 25Paclitaxel 19Magnetic Resonance Spectroscopy 19Radiotherapy, Intensity-Modulated 17Nivolumab 17Radiotherapy 16Specimen Handling 15Docetaxel 14Platinum 131,2-diaminocyclohexaneplatinum II citrate 12Taxes 8Fluorouracil 8Biopsy 8atezolizumab 6Radiation 6(225)Ac-DOTA-c(RGDyK) 6dostarlimab 5cemiplimab 5Ipilimumab 5Immunoglobulin G 5Cyclophosphamide 5Surgical Procedures, Operative 4Standard of Care 4Immune Checkpoint Inhibitors 4Disulfides 4Bevacizumab 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Rosiglitazone × 90 days × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡